Emerging pharmacological therapies for prevention and early treatment of acute lung injury.
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40%. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Enrique
E
Ortiz-Diaz
Emir
E
Festic
Ognjen
O
Gajic
Joseph E
JE
Levitt
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D000818:Animals; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D012307:Risk Factors; D013997:Time Factors